Zetagen is committed to the treatment of metastatic cancer lesions to bone and other soft tissue organs. Bone metastases are common among cancer patients and occur when cells from the primary cancerous tumor relocate to the bone. When these cancers relocate, they can cause changes to the bone, damaging it in a process called osteolysis. Osteolysis can cause small holes within the bone, weakening it and increasing the risk of breakage. These holes are called “lytic lesions.” Among cancers which metastasize to bone, Breast and Prostate are most prevalent, amounting to approximately 70-percent of cases.[1]
Lytic lesions can cause severe, debilitating pain in patients with advanced cancer. Patients with these lesions often experience a reduced quality of life with multiple skeletal-related events (SREs), including fractures, spinal cord compression, elevated levels of calcium in the blood or “hypercalcaemia”, bone marrow infiltration and severe bone pain.[2] Bone metastases are also a major cause for morbidity in patients with advanced stage cancer.[3]
The Standard of Care (SOC) prescribes external single or fractionated radiation therapy (RT) as a palliative procedure to manage pain, that on average provides durable effective pain relief for six (6) months[1,2]. The median survival rate following the SOC RT for metastases to bone is between 5 to 9 months [2,3]. The SOC RT has not been shown to change the likelihood of preventing pathologic fracture[4]. The survival rate following a skeletal related event (SRE) that includes fracture is 4.8 months following the SOC.[5]
Our product, ZetaMet™ (Zeta-BC-003) has thus far demonstrated its ability to resolve existing metastatic bone lesions, inhibit pain, stimulate targeted bone regeneration with the potential increase survival rates.
